TG Therapeutics | TGTX - Current Assets


TG Therapeutics reported $1.15B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Alaunos Therapeutics USD 666K 304K Jun/2026
Amgen USD 34.36B 598M Sep/2026
Ardelyx USD 441.39M 538K Sep/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Bayer EUR 39.6B 5.96B Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
Corcept Therapeutics USD 533.87M 94.2M Sep/2026
Curis USD 16.61M 9.7M Mar/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Novartis USD 28.75B 1.4B Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Verastem USD 202.9M 20.51M Mar/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026